Search

Your search keyword '"Peña FA"' showing total 2 results
Start Over Author "Peña FA" Topic biomarkers, tumor
2 results on '"Peña FA"'

1. Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain.

Author

Rodríguez-Lescure A, de la Peña FA, Aranda E, Calvo A, Felip E, Garrido P, and Vera R

Subjects
Clinical Decision-Making, Humans, Neoplasms drug therapy, Neoplasms mortality, Spain, Surveys and Questionnaires, Time Factors, Antineoplastic Agents supply & distribution, Biomarkers, Tumor analysis, Drug Approval, Medical Oncology, Societies, Medical
Abstract

Purpose: The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed., Methods: A questionnaire was sent to 146 hospitals in Spain to collect information on the process of approval of 11 oncology drugs of an unquestionable clinical benefit and five predictive biomarkers of mandatory determination for specific treatments., Results: Results highlight the still existing differences in the access of oncology drugs, as well as the newly identified differences in the access to predictive biomarkers between Autonomous Communities (AACC) in Spain, as well as between different hospitals within the same Autonomous Community. Conclusions The SEOM considers it necessary to reduce the differences identified, increase homogeneity, and improve conditions of access to oncology drugs and biomarkers, and makes proposals to address these issues.

Published
2020
Full Text
View/download PDF

2. Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain

Author

Rodríguez-Lescure, A., de la Peña, F. A., Aranda, E., Calvo, A., Felip, Enriqueta, Garrido, Pilar, Vera, Ruth, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Rodríguez-Lescure A] Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain. [de la Peña FA] Haematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain. [Aranda E] Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain. [Calvo A] Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Garrido P] Medical Oncology Department, Hospital Universitario Ramón Y Cajal, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Time Factors, Oncologia, Clinical Decision-Making, factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS], Antineoplastic Agents, Medical Oncology, 03 medical and health sciences, profesiones sanitarias::medicina::medicina interna::oncología médica [DISCIPLINAS Y OCUPACIONES], 0302 clinical medicine, Internal medicine, Neoplasms, Surveys and Questionnaires, Biomarkers, Tumor, Medicine, Humans, 030212 general & internal medicine, Biological Factors::Biomarkers::Biomarkers, Tumor [CHEMICALS AND DRUGS], Health Occupations::Medicine::Internal Medicine::Medical Oncology [DISCIPLINES AND OCCUPATIONS], Drug Approval, Societies, Medical, Predictive biomarker, Medicaments - Desenvolupament, técnicas de investigación::desarrollo de medicamentos::autorización de medicamentos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], business.industry, Marcadors tumorals, General Medicine, Biomarker, Equity, Access, Clinical Practice, Spain, 030220 oncology & carcinogenesis, Drug, business, Oncology drugs, Investigative Techniques::Drug Development::Drug Approval [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Barriers, Research Article
Abstract

Purpose The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed. Methods A questionnaire was sent to 146 hospitals in Spain to collect information on the process of approval of 11 oncology drugs of an unquestionable clinical benefit and five predictive biomarkers of mandatory determination for specific treatments. Results Results highlight the still existing differences in the access of oncology drugs, as well as the newly identified differences in the access to predictive biomarkers between Autonomous Communities (AACC) in Spain, as well as between different hospitals within the same Autonomous Community. Conclusions The SEOM considers it necessary to reduce the differences identified, increase homogeneity, and improve conditions of access to oncology drugs and biomarkers, and makes proposals to address these issues.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results